31

Mar2020

PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers

We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More

19

Mar2020

PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation

The full list of submissions can be found here under the Submissions tab at the bottom of the page. Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ... Read More

16

Mar2020

PDCI Business Operations: Business [Almost] as Usual!

Good Afternoon, At PDCI Market Access Inc. (“PDCI”) we are committed to providing high quality services and deliverables to our clients. We also recognize the important responsibility we all have to prevent the spread of the COVID-19 outbreak. Based on the information received to date, we are currently implementing the following accommodations ... Read More

10

Mar2020

PMPRB Cancellation of March 18th Policy Forum

PMPRB Cancellation of March 18th Policy Forum The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation. In order to provide stakeholders with an opportunity to convey information that may ... Read More

26

Feb2020

Introducing Between the Lines: A Canadian Pharmaceutical Industry Podcast

PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy ... Read More

24

Feb2020

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2020

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since ... Read More

14

Feb2020

CADTH Releases Pharmaceutical Reviews Update – Issue 13

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website. In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More

13

Feb2020

PDCI Analysis Estimates Impact of PMPRB Draft Guidelines to be up to $41.8 Billion

Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines. Top-Line Summary The PMPRB regulatory changes and Draft ... Read More

29

Jan2020

PDCI’s New Associate Director, HTA and Clinical Evaluation

PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation. Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More

15

Jan2020

Status Summary of Innovative Medicine pCPA Negotiations as of December 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA ... Read More